Author:
Song J H,Kweon S H,Kim H-J,Lee T-H,Min W-S,Kim H-J,Kim Y-K,Hwang S Y,Kim T S
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 104: 11014–11019
2. Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ, Cass CE, Gros P (2008) Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 68: 2349–2357
3. Carella AM, Berman E, Maraone MP, Ganzina F (1990) Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica 75: 159–169
4. Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E (2006) Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia 8: 38–45
5. Chen CC, Gau JP, You JY, Lee KD, Yu YB, Lu CH, Lin JT, Lan C, Lo WH, Liu JM, Yang CF (2009) Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia. Am J Hematol 84: 87–92
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献